Clinical Trial Update: Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion [Phase 2]

View source ↗

Summary

Phase 2 trial assessing idelalisib plus rituximab in previously untreated CLL with 17p deletion; study terminated with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Idelalisib (idelalisib)
• Rituximab (rituximab)

Snippet

Sponsor: Gilead Sciences | Conditions: B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion | Phase 2 | Status: TERMINATED | Results posted: 2017-05-11